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Abstract
Toll-like receptors are important in the activation of innate immunity, and CD40 is a molecule
critical for many T and B cell responses. Whereas agonists for either pathway have been used as
vaccine adjuvants, we show that a combination of Toll-like receptor (TLR)7 and CD40 agonists
synergize to stimulate CD8 T cell responses 10–20-fold greater than the use of either agonist
alone. Antigen-specific CD8 T cells elicited from combination CD40/TLR7 treatment demonstrated both lytic activities and interferon (IFN) production and an enhanced secondary
response to antigenic challenge. Agonists for TLRs 2/6, 3, 4, and 9 also synergized with CD40
stimulation, demonstrating that synergy with the CD40 pathway is a property of TLR-derived
stimuli in general. The CD8 T cell expansion induced by CD40/TLR7 triggering was independent of CD4 T cells, IFN, and IL-12 but dependent on B7-mediated costimulation and
surprisingly on type I IFN. These studies provide the rational basis for the use of TLR and
CD40 agonists together as essential adjuvants to optimize vaccines designed to elicit protective
or therapeutic immunity.
Key words: Toll like receptor • TLR7 • CD40 • CD8 • T cell

Introduction
The magnitude and quality of the innate immune response
exerts a profound impact on the ensuing adaptive immune
response. Inflammatory cells and mediators generated as a
result of initial tissue injury, infection, or necrotic death
serve as initiators of a cascade of events that, when successful,
culminates in the generation of productive T and B cell
responses and long-term immunity. A family of receptors
known as the Toll-like receptors (TLRs), named for their
homology to molecules in Drosophila that serve functions in
development and antimicrobial immunity (1), are critical to
the ability of the cells of the innate immune system to respond
to microbial and viral infections. Over the past few years, the
macromolecules recognized by TLRs have been identified.
Agonists for TLRs include the inflammatory mediators tri-acyl
lipopeptides (TLR1), lipoteichoic acid (TLR2), dsRNA
(TLR3), LPS (TLR4), flagellin (TLR5), diacyl lipopeptides
(TLR6), imidazoquinolines (TLR7, TLR8), and CpGs
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(TLR9) (2). Activation of cells through TLRs elicits a variety
of inflammatory cytokines and chemokines depending on
the cell type and specific TLR being stimulated. As a testament to the importance of TLRs in immunity, TLR knockouts and knockouts of molecules critical to TLR signaling,
such as MyD88 and TIRAP, result in the elimination of the
majority of innate inflammatory mediators and a dramatic
reduction in T and B cell responses (3–8).
The low molecular weight molecules known as imidazoquinolines or immune response modifiers (IRMs) have significant immunomodulatory capabilities and have been
shown recently to be agonists for TLR7 in mouse and
TLR7 and 8 in humans (9–11). Similar to other TLR agonists, IRMs such as imiquimod, resiquimod (R-848), and
S-27609 (27609) induce a variety of cellular effects such as
DC cytokine production, migration, and activation marker
up-regulation, and B cell activation (12–15). Furthermore,
IRMs induce significant amounts of type 1 IFN from the
plasmacytoid DCs (9, 10, 16) in several species (15, 17, 18).
Abbreviations used in this paper: IRM, immune response modifier; TLR,
Toll-like receptor.
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The central role played by TLRs in triggering innate immunity is mirrored by CD40 in controlling acquired immune responses. CD40, a TNFR superfamily member, is
essential for a spectrum of cell-mediated immune responses
and required for the development of T cell–dependent humoral immunity (19–21). The expression of CD40 on
APCs (DCs, macrophages) and on B cells (19–23) provides
an understanding for its profound impact on both arms of
the acquired immune response. Stimulation through CD40
has been shown to induce the generation of CD4-independent CD8 T cell responses (24–27). These reports speculated that CD40 agonists could potentially rescue failing
CD4-dependent CD8 T cell responses in some disease settings. Although data has supported the observation that
CD40 has effects on long-term T cell survival (24, 28, 29),
other data demonstrated that CD40 agonists alone are not
sufficient to generate protective antitumor immunity or
long-term immunity (30–32). In these cases, CD40 agonists
used as a monotherapy have been shown to induce the deletion of antigen-specific T cells and cause the premature
termination of humoral (32) and cellular (30, 31) immunity.
In the present study, we asked how the concomitant delivery of TLR and CD40 agonists enhanced antigen-specific, acquired immune responses. Although antigenic challenge in conjunction with either CD40 or TLR7 agonists
alone elicited a minimal, though detectable, primary CD8
T cell response, the combination of both agonists induced
an exponential expansion of antigen-specific T cells. The
combination of agonists induced heightened T cell expansion, high levels of lytic activity and cytokine production,
and the development of a functional memory T cell pool.
Interestingly, this synergy was a property of multiple TLR
agonists including TLRs 2/6, 3, 4, and 9. Although the T
cell expansion was not dependent on CD4 cells or IL-12,
IL-23, or IFN, synergy resulting from most, though not
all, TLR agonists was dependent on type I IFN. Hence,
the use of a CD40 agonistic antibody in conjunction with a
low molecular weight TLR7 agonist can reconstitute all of
the signals required to elicit profound acquired cell-mediated immunity.

Materials and Methods
Mice. C57BL/6 (Ly5.1) mice were purchased from National Cancer Institute and Charles River Laboratories and
housed under specific pathogen-free conditions. B6.129S1Il12atm1Jm, B6.129S1-Il12btm1Jm, B6.129P2-Tnfrsf5tm1Kik, B6.129S4CD80tm1ShrCD86tm1Shr, B6.129S7-Ifngtm1Ts, and B6.129S2CD4tm1Mak mice were purchased from The Jackson Laboratory.
B6.129-AbbTm1N5 and B6/129 F1 mice were purchased from
Taconic Farms Inc. MyD88 KO mice were a gift from Dr.
Douglas T. Golenbock (University of Massachusetts Medical
School, Worcester, MA) and were bred at Dartmouth College.
IFNR KO mice were a gift from Dr. Philippa Marrack (National Jewish Medical and Research Center, Denver, CO) and
were bred on site at 3M Pharmaceuticals.
Monoclonal Antibodies. The following antibodies were purchased from BD Biosciences: anti–mouse CD8-APC (Ly-2),
anti–mouse CD44-FITC (Pgp-1, Ly-24), and B220-Cy (RA3–
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6B2). CD40 (1C10 or FGK45) were produced by hybridomas
that were grown in serum-free conditions. Ova-specific CD8 T
cells were detected by H-2K b–specific tetramers containing the
SIINFEKL peptide, either made as described previously (33) (a
gift from Dr. Lefrancois, University of Connecticut Health Center, Farmington, CT) or purchased from Beckman Coulter.
TLR Agonists. The IRM 1-(4-amino-2-methyl-1 H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol hydrochloride
(S-27609) was synthesized as described previously (15). It was reconstituted in water at 10 mg/ml and diluted in PBS for injection
into mice. Other TLR agonists used were CpG 1826 (Invitrogen
Life Technologies), LPS (Sigma-Aldrich), polyinosinic-polycytidylic acid (polyI:C) (Amersham Biosciences), Malp-2 (Alexis
Biochemicals), and S-27609 (3M Pharmaceuticals).
Immunization. 6–12-wk-old female C57BL/6J mice were injected i.p., unless otherwise noted, with 0.5 mg whole ovalbumin
(Sigma-Aldrich) with or without varying amounts of TLR agonists and/or 50 g of 1C10 or FGK45 (anti-CD40). Where peptide injections are noted, mice were injected with anti-CD40 i.p.
and then 4–6 h later injected i.v. with 100 mg SIINFEKL peptide
and a given TLR agonist. Anti-CD40 was used at 50 g per injection. Mice were immunized with a single injection i.p. and
killed 6 d later unless otherwise noted.
Cell Preparation. 6 d after i.p. injections, spleens were removed and homogenized into single cell suspensions. RBCs
were lysed using an ammonium chloride buffer followed by
washing. Cells were resuspended in complete medium (SMEM
[Biosource International], 10% heat-inactivated FBS [Hyclone], 1
mM sodium pyruvate, 0.1 mM nonessential amino acids, 1%
PenStrep, and 1% l-glutamine [Sigma-Aldrich]). Cells were resuspended at 2–4  107 cells/ml.
Analysis of MHC Tetramer by Extracellular Staining and Flow Cytometry. Cells were plated in duplicate in 96-well round-bottomed plates and stained with K b/ovalbumin tetramer (33) for
1–2 h at room temperature (RT) or 37 C. Multiparameter analysis of tetramer-positive cells was afforded by staining cells (30 min
at 37C or RT) with anti-CD44–FITC, anti-Y3P–TNP, antiB220–cychrome, and anti-CD8–APC. Cells were then washed
in FACS ® buffer, and four-color FACS ® data was collected
on a BD FACSCalibur flow cytometer and analyzed using
CELLQUEST software. Analysis typically gated on CD8 ,
MHC class II cells to assess tetramer staining.
Analysis of IFN- by Intracellular Staining and Flow Cytometry.
Cells were plated in 96-well round-bottomed plates and pulsed
with SIINFEKL peptide as antigen (or without antigen as a control) in the presence of Golgi-plug (BD Biosciences) (brefeldin A)
for 4–6 h in complete media at 37 C. Cells were stained using
anti-CD4–cychrome and anti-CD8–FITC. After washing, cells
were fixed using Cytofix (BD Biosciences) for 15 min. Cells
were then washed and permeabilized using Perm/Wash (BD
Biosciences). Intracellular staining for IFN- –APC was then performed according to the BD Biosciences protocol. Four-color
FACS® data was collected on a BD FACSCalibur flow cytometer
and analyzed using CELLQUEST software to quantify CD8  T
cells producing IFN.
In Vivo Cytotoxicity Assay. Syngeneic splenocytes were labeled with either 0.5 or 5 M CFSE for 15 min at 37C and
washed twice. CFSEhigh cells were subsequently pulsed with 50
g/ml SIINFEKL peptide for 60 min at 37 C. CFSElow cells
served as an internal control and therefore were not pulsed with
peptide. Cells were mixed at a 1:1 ratio, and then 5  106 total
cells were injected i.v. into mice challenged previously with combinations of antigen, TLR agonist, and CD40 as described above.
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12–18 h later, splenocytes from each mouse were analyzed by
FACS® to detect the presence of CFSE-labeled cells. The ratio of
antigen-unpulsed, low CFSE cells to pulsed, high CFSE labeled
cells was calculated as an indication of antigen-specific lytic activity.

Results
Concomitant Administration of TLR and CD40 Agonists Induce
the Synergistic Expansion of Antigen-specific CD8 T Cells.
Previous studies have shown that CD40 triggering of DCs
can enhance CTL activation and replace the need for T cell
help (24–27). However, emerging data suggest that TLR
triggering may be critical at optimizing CD40-induced
maturation of DCs (34, 35). No studies thus far have exhaustively evaluated the impact of combined TLR and
CD40 engagement on the CD8-acquired immune response. To this end, mice were immunized with 500 g
soluble OVA protein combined with an agonistic antiCD40 mAb and/or the TLR7 agonist, S-27609 (27609)
(13) (Fig. 1 A). Expansion of antigen-specific CD8 T cells
in vivo was quantified by staining with an OVA H-2 Kb
tetramer 6 d after immunization. As has been shown previ-

ously by Lefrancois et al., the administration of anti-CD40
and OVA can enhance the accumulation of tetramer-positive cells (24). Compared with the soluble OVA alone,
modest enhancements in tetramer-positive CD8 T cells
appeared with OVA and anti-CD40 or S-27609 (Fig. 1 A).
However, combined administration of OVA, anti-CD40,
and S-27609 induced a synergistic accumulation of tetramer-positive cells. To determine whether the synergy
between the TLR7 and CD40 would enhance CD8 T
cell responses at more limiting antigen doses as well, we
immunized mice with decreasing amounts of ovalbumin
peptide (Fig. 2 B) or protein (Fig. 2 C), and the CD8 T
cell response was assessed as before. As expected, cotriggering of CD40 and TLR7 induced a significant expansion of
antigen-specific CD8 T cells well above that ( 10-fold)
seen with antigen and CD40 alone even down to as little as
5 g of peptide or 100 g of protein.
The kinetics and antigen dose response of the OVAspecific CD8 T cell responses to combined CD40/TLR
administration was evaluated. As seen in Fig. 1 D, combined TLR and CD40 triggering induces a rapid expanFigure 1. Anti-CD40 and the
TLR7 agonist 27609 synergize
to induce enhanced CD8 T cell
expansion. (A) C57BL/6 mice
were immunized i.p. with 500
g of whole ovalbumin protein,
50 g of the anti-CD40 antibody
FGK45, and 100 g of 27609 in
the combinations indicated above.
Mice were killed 6 d after immunization, and spleen cells were
isolated and stained with tetramer
as described in Materials and
Methods to identify ovalbuminspecific T cells. The data shown
has been gated on all CD8,
B220 events. The percentages
given in the top right quadrant
are the percentage of tetramer
staining cells out of total CD8
T cells. (B and C) Mice were immunized as in A with increasing
amounts of peptide i.v. (B) or
whole ovalbumin (C) and antiCD40
27609 i.p. 6 d after
priming, the spleen cells were
stained and analyzed as in A for
ovalbumin-specific T cells. Percentages given are tetramer staining cells out of total CD8 T
cells. Error bars represent SD of
three mice per group. (D) Mice
were immunized as in A with
whole ovalbumin, anti-CD40, and
27609, and at the times indicated
after priming, the spleen cells
were removed and analyzed as in
A. The data shown was gated on
all live, CD8, B220 events.
The percentages given in the top
right quadrant are the percentage
of tetramer staining cells out of
total CD8 T cells.
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Figure 2. CD40/TLR7 triggering induces
functional CTL. (A) Mice primed with 500 g
whole ovalbumin
CD40 and/or S-27609
were assessed by using an in vivo cytotoxicity
assay as described in Materials and Methods.
The number in the top left of the histograms
indicates the ratio of nonantigen pulsed, low
CFSE-labeled spleen cells to antigen pulsed,
high CFSE-labeled spleen cells. (B) As in A,
mice were immunized and analyzed by tetramer
staining and in vivo cytotoxic activity at the
time points indicated. (C) Cells from mice
treated as in A (day 7 after priming) were incubated in the presence of brefeldin A with or
without SIINFEKL peptide for 6 h at 37. The
cells were then stained for CD8, fixed, permeabilized, and stained for intracellular IFN as
described in Materials and Methods. The data
shown is gated on all CD8 events. Numbers in
the top right quadrant indicate the percentage
of IFN cells out of the total CD8 cells.

sion in response to protein immunization followed by a
contraction of antigen-specific CD8 T cells. The peak
accumulation of antigen-specific CD8 T cells was observed on day 6 postadministration of antigen, TLR, and
CD40 agonists. After the day 6 peak, a rapid contraction
in CD8 T cell numbers was observed by day 9. The
magnitude of the CD8 response elicited by the combined
triggering of CD40 and TLR is similar to that seen in antiviral responses, such as responses against LCMV (36). The
time course of the response after peptide immunization
was essentially indistinguishable from protein immunization (not depicted).
TLR7/CD40 Synergy Induces Functional CTL. In addition to CD8 T cell expansion, CTL killing activity and
expression of IFN were evaluated. On days after immunization, in vivo CTL activity was measured (37–40). The in
vivo CTL assay showed that cotriggering of CD40 and
TLR7 induced significant lytic activity (Fig. 2 A). Detectable lytic activity was present in the immunized mice from
day 5 through 12 (Fig. 2 B). Cotriggering of CD40/TLR7
also elicited intracellular expression of IFN (Fig. 2 C),
though CD40 stimulation alone also induced detectable
IFN production (Fig. 2 C) from the cells from this time
point. IFN production was first detected on day 6 after
priming (5–20% of Ag-specific T cells) and peaked by day
7–8 (60–90% of Ag-specific T cells) (not depicted and Fig.
1 C). Therefore, the data show that the combined actions
778

of CD40 and TLR7 agonists resulted in antigen-specific T
cell expansion and differentiation.
TLR/CD40 Triggering Elicits Long-Term, Antigen-specific
CD8 T Cell Immunity. The fate of the TLR/CD40induced T cells was evaluated to determine if the initial expansion and contraction of the tetramer-positive T cells lead
to anergy or memory. Numerous models exist whereby dramatic T cell expansion is followed by an equally dramatic
demise in T cell numbers and function, leaving any remaining cells in a hyporesponsive state of tolerance (30, 36, 41–
44). Alternatively, productive responses present the same
patterns of expansion and contraction, yet upon rechallenge,
secondary expansion can be observed. Mice initially immunized with OVA, anti-CD40, and S-27609 were rechallenged 30 d after initial priming with combinations or CD40
and TLR7 agonists and either peptide (Fig. 3, top) or protein (Fig. 3, bottom). The secondary response was less reliant
on costimulatory signals than the primary response, demonstrating a detectable increase in tetramer-staining cells in response to protein or peptide rechallenge alone. The addition
of the TLR7 agonist to peptide rechallenge elicited a better
(enhanced) response compared with peptide alone, which
peaked on day 3 after rechallenge. In contrast, rechallenge
with protein was enhanced when CD40 was added and the
response peaked on day 5 after rechallenge. This difference
between peptide and protein rechallenge in the time of the
peak of the response likely reflects the additional time neces-
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Figure 3. TLR/CD40 triggering produces
long-term T cell immunity. (A) Mice were
immunized i.p. with ovalbumin, anti-CD40,
and S-27609 as in Fig. 1. 30 d later, the mice
were rechallenged i.p. with either 100 g SIINFEKL peptide or 500 g ovalbumin protein 27609/CD40 as indicated. At days 3 and
5 after rechallenge, spleen cells were isolated
and stained with tetramer as described in Materials and Methods. Peak responses for peptide or
protein responses are shown (day 3 for peptide
rechallenge and day 5 for protein rechallenge).
The data shown was gated and analyzed as in
Fig. 1 A. The data is representative of three experiments performed.

sary for processing and presentation of the protein. The enhancement of the protein response with anti-CD40 is also
consistent with the role of CD40 in augmenting crosspriming. CD40 did enhance the peptide response compared with
peptide alone, but for reasons that are not clear, this response
peaked on day 5 and was not any greater than the day 3 response to peptide and the TLR7 agonist (not depicted). In
all cases, the secondary response was more rapid but lower
than the peak of the primary response. This has been is seen
in other experimental systems (41, 45, 46) and is probably
due to the rapid clearance of the antigen by the high frequency of functional memory cells. In general, the data
demonstrate that the primary response generated by immu-

nization in the combined presence of CD40 and TLR7 agonists leads to the generation of functional memory CTLs.
Synergy with CD40 in the Induction of CD8 T Cell Proliferation and Differentiation Is a Property of Multiple TLR Agonists. CD40 has been used in combination with a variety
of stimuli and has been shown to enhance immune responses (28, 33, 47). We considered the possibility that the
synergy we observed between TLR7 and CD40 was a
property of TLR agonists in general and not necessarily of
only TLR7 agonists. Mice were immunized with antiCD40, ovalbumin protein (Fig. 4, A and B), or peptide
(Fig. 4 C) and agonists for TLR 2/6, 3, 4, 7, or 9. 6 d after
the administration of these agents, the frequency of OVA-

Figure 4. Synergy with CD40 in the induction of CD8 T cell proliferation and differentiation is a property of multiple TLR agonists. (A) Mice were
challenged i.p. with ovalbumin and the indicated TLR agonists (30 g LPS as a TLR4 agonist, 100 g CpG 1826 as a TLR9 agonist, 25 g Malp-2 as a
TLR2/6 agonist, 50 g poly IC as a TLR3 agonist, and 100 g 27609 as the TLR7 agonist), with or without anti-CD40. 6 d after challenge, spleens
cells were isolated and stained with tetramer as described in Fig. 1. The data shown was gated and analyzed as in Fig. 1 A. (B and C) The average percentage
of tetramer staining T cells and their SDs from three mice per treatment primed with whole protein (B) or peptide (C) were analyzed and calculated. The
data shown is representative of three to eight experiments performed, depending on the TLR agonist.
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Figure 5. TLR/CD40 triggering of CD8 T cell expansion and effector function is largely dependent on costimulation via CD80/86 but independent
of CD4 cells, IFN, IL-12, or IL-23. The indicated genetically deficient mice were immunized with 500 g ovalbumin plus 50 g anti-CD40 and 200
g 27609 by i.p. injection. On day 6 postimmunization, in vivo lytic activity was measured as in Fig. 2 A, and splenocytes were isolated and analyzed as
in Fig. 1 but using anti-CD8 PE and APC-labeled SIINFEKL/H-2Kb tetramers. Data is representative of at least three mice per group. Numbers in the
top right quadrant of the dotplots indicates the percentage of tetramer CD8 T cells out of total CD8 T cells. The number in the top left of the histograms indicates the ratio of nonantigen pulsed, low CFSE-labeled spleen cells to antigen pulsed, high CFSE-labeled spleen cells.

specific T cells was determined as before. With respect to
OVA-specific tetramer-positive CTL expansion, all TLR
agonists demonstrated synergy with the CD40 agonist (Fig.
4 A), though each TLR agonists synergized to varying degrees with CD40 (Fig. 4, B and C). As with the TLR7 agonist, all of the TLR agonists elicited IFN production from
the T cells as well (not depicted). Therefore, signals derived
from a variety of TLRs are able to synergize with CD40
signaling to induce T cell expansion and differentiation.
TLR7/CD40 Triggering of CD8 T Cell Expansion Is Independent of CD4 Cells, IFN, IL-12, or IL-23. CD8 T
cell responses have been shown to be either dependent or
independent of CD4 T cells or cytokine-mediated help
(48). To determine which cellular and molecular components influenced the magnitude of the CD8 T cell response induced by CD40 and TLR7 agonists and antigen, a
series of studies in genetically deficient mice were performed (Fig. 5). The magnitude of the CD8 expansion or
differentiation to lytic function induced by immunization
with OVA and CD40 and TLR7 agonists was not diminished in either CD4 / or class II MHC / mice, demonstrating the helper independent nature of this form of priming. Additionally, neither IL-12, IL-23, nor IFN were
required, as expansion in IL-12p35 /, IL-12p40 /, and
IFN / mice, respectively, were similar to WT mice.
Costimulation via CD28 was deemed critical as expansion
in the CD80/CD86 / mice was ablated. Reaffirmation of
the functional importance of CD40 and the TLR signaling
pathway (2) was demonstrated by the lack of expansion of
tetramer-positive cells in CD40 / and MyD88 / mice.
Thus, other than classical B7-mediated costimulation,
which is a property of T cell responses in general, the induction of primary immunity by TLR/CD40 cotriggering
is independent of IL-12, IL-23 (49), IFN, and the presence of CD4 helper cells.
Dependence on Type I IFN Varies with the Specific TLR Agonist Employed. In previous experiments, it was observed
that the TLR agonists that synergized with CD40 to produce the highest level of CD8 T cell expansion (poly
IC and 27609) were also potent inducers of type I IFN
780

(IFN/) (Fig. 3). We sought to determine whether
IFN/ contributed to CD8 T cell expansion by performing experiments in IFN/ receptor knockout mice
(IFN/R KO). Surprisingly, the synergy between CD40
and TLR7 was essentially abrogated in IFN/R KO
mice with the CD8 T cell expansion being reduced down
to that seen in the presence of anti-CD40 alone (Fig. 6 A).
However, the TLR agonists that induced the least IFN
appeared to induce synergy that was least affected by the
loss of type I IFN signaling (Fig. 6, A–C). For example, in
response to peptide immunization (Fig. 6, A and B) Malp-2
(TLR2/6 agonist) synergy with CD40 was only modestly
affected in the IFNR KOs (60–90% of max), whereas
LPS, CpG, polyI:C, and 27609 were increasingly affected
(respectively) in the absence of the IFN receptor. In
contrast, synergy with all TLR agonists was all but abrogated when the mice were challenged with protein instead
of peptide (Fig. 6 C). This is consistent with recent literature reporting that type I IFN facilitates crosspriming in
APC (50, 51). However, the loss of synergy in response to
priming with peptide (Fig. 6, A and B) demonstrates that
for all TLR agonists but Malp-2, type I IFN plays a larger
role than just enabling crosspriming. Thus, the data suggests that synergy between the TLR pathway and the
CD40 pathway is best observed under conditions where
the TLR agonist induces type I IFN and further that the
CD8 T cell expansion seen under these conditions is dependent on some aspect of type I IFN signaling.

Discussion
The work presented here demonstrates that the concomitant signaling via TLR and CD40 results in a synergistic
increase in expansion of antigen-specific CTL and their
differentiation to effector cells. The combination of TLR7
and CD40 agonists synergized to stimulate heightened
CTL proliferation and function with respect to IFN production and lytic activity. The high level of CD8 T cell
proliferation seen was neither abortive nor exhaustive (30,
36, 42, 43), since the mice generated secondary T cell ex-
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Figure 6. CD40 synergy with IFN/-inducing TLR agonists is critically dependent on type I IFN. Either wt control B6/129 F1 or IFNR KO
mice were immunized with 100 g of SIINFEKL peptide (A and B) or 500 g ovalbumin protein (C), 50 g anti CD40, and the indicated TLR agonist
(30 g LPS as a TLR4 agonist, 100 g CpG 1826 as a TLR9 agonist, 25 g Malp-2 as a TLR2/6 agonist, 50 g poly IC as a TLR3 agonist, and 100 g
27609 as the TLR7 agonist) as in Fig. 3. On day 6, spleen cells were stained with tetramer and analyzed as in Fig. 1 A. The legend above the figure indicates
the TLR agonist used. (B and C) The percentage of tetramer staining cells in the mice from A after either peptide (B) or whole protein (C) challenge
were calculated as the percentage of tetramer staining cells out of total CD8 T cells. This percentage was then divided by the percentage of tetramer
staining cells from wild-type mice challenged with the same TLR agonist. The data is expressed as the percentage of maximum synergy seen in the
IFNR KO mice compared with the wild type for the given TLR agonist. The data shown is an average from three mice per treatment group, and
error bars indicate the calculated SD. The data represents three experiments performed.

pansion upon rechallenge with antigen with or without
TLR7/CD40 agonists. These memory T cells expressed all
of the hallmarks of a functional secondary response, i.e., responding more rapidly and with a reduced dependency on
adjuvant compared with the primary response (46, 52–55).
Of particular interest was the fact that TLR 2/6, 3, 4, and 9
agonists also were capable of synergizing with anti-CD40
to induce the expansion of OVA-specific CD8 T cells,
with the TLR agonists that generated higher levels of type
I IFN tending to produce the highest levels of T cell expansion. Thus, some aspect of TLR and CD40 signaling
must have a general point of intersection, an observation
that is consistent with the biology of the receptors, i.e.,
APC could receive an initial activation stimulus through a
TLR at the site of infection and after migration to the T
cell zones of the lymphoid tissue receive a CD40 stimulus
from antigen-specific T cells, effectively “confirming” the
APC’s activation and further reinforcing T cell expansion.
Previous studies have suggested that, at least in certain
circumstances, CD40 stimulation could rescue defective or
abortive CD8 T cell proliferation and effector cell function. Indeed, these reports demonstrated that CD40 stimulation alone allowed normally CD4-dependent CD8 T
781

Ahonen et al.

cell responses to proceed in the absence of CD4 help (24–
27), implicating CD40 signaling as the primary mechanism
of CD4 help for CTL proliferation. More recent reports
have further suggested that at least in some disease and experimental models CD40 stimulation alone was necessary
and sufficient to initiate long-lived CTL expansion and effector function (24, 28, 29). However, this is not the case
in all systems and models tested. Both IL-12 production
(34) and antitumor CTL responses (30) have been shown
to be dependent on CD40 in combination with other bacterial/viral-derived stimuli. Indeed, some studies have
demonstrated that CD40 stimulation alone resulted not in
immunity but in deletion of antigen-specific T cells (30,
31) and termination of humoral responses (32). Our data
demonstrates that although CD40 is able to induce CD8
T cell immunity to a limited degree, this can be exponentially enhanced by the addition of a TLR agonist. Therefore, we would predict that the clinical efficacy of CD40
agonists could be dramatically improved if provided in
conjunction with an appropriate antigen and TLR agonist,
specifically a TLR7 agonist, as our data demonstrates.
CD40 is expressed on APCs (DCs, macrophages, B
cells), and it is generally agreed that stimulation through

CD40 plays a role in the activation of APCs to become
competent to initiate CD8 T cell proliferation. In contrast, a report from Bourgeois et al. has demonstrated that
CD8 T cells can express CD40 after activation and that
this expression of CD40 on the T cells may play a greater
role in CD8 T cell proliferation than CD40 expression on
the APC (56). Given this observation, it is possible that the
synergy we demonstrate between TLR and CD40 agonists
is due to direct stimulation of CD40 on the antigen-specific T cells themselves and not on the APC. However, a
recent report from Lee et al. shows that CD8 responses to
influenza are dependent on CD40 expression on the APC
and that neither the APC nor the CD4 T cells directly
stimulate CD8 T cells through CD40–CD40L interactions
(57). This study showed through various bone marrow chiCD8 T cells expanded as well as
meras that CD40
CD40  CD8 cells in host, strongly arguing against a
functional role for CD40 expression on the CD8 T cells.
However, we cannot as of yet rule out a role for direct
stimulation of CD40 on the T cells in the CD8 T cell expansion seen in our model system. Experiments are in
progress to determine whether CD40 expression on APC
or T cells is necessary for this synergistic induction of T cell
expansion by the cotriggering of TLR/CD40.
Perhaps the most interesting feature of the observed synergy is its variable dependence on type I IFN. In general,
the data is consistent with the interpretation that the degree
of synergy is related to and dependent on the level of IFN
induced by the TLR agonists. However, the TLR2/6 agonist Malp-2 (58, 59) appears to be somewhat of an exception to that rule. TLR2 agonists have been shown to induce
little to no type I IFN (3, 60, 61), but Malp-2 demonstrated
significant levels of synergy with CD40 nonetheless. Therefore, the data suggest that there are at least two ways that
TLRs synergize with CD40: one mediated through type I
IFN signaling and the other mediated through some aspect
of Malp-2 signaling. We have demonstrated that for those
TLR agonists that induce either IFN or , synergy with
CD40 is increasingly dependent on type I IFN. However, it
is currently unclear given the almost ubiquitous expression
of the IFN receptor, in which cell type(s) IFN signaling
is necessary for producing this synergy. Interestingly the
TLR/CD40-triggered CD8 T cell expansion in the IFNR KO mice was reduced to a greater extent in response
to whole protein antigen challenge, even when using Malp-2
as the TLR agonist. This further supports the identified role
of type I IFN in crosspriming (50, 51) and demonstrates that
at least some, though not all, aspects of TLR/CD40-induced
synergy are mediated by the effects of IFN on antigen processing and presentation.
In conclusion, these studies underscore the powerful immune synergy that exists when receptors from both innate
and acquired immunity are triggered. It is tempting to speculate that the TLR and CD40 signaling cascades evolved
the means for cross talk and integration so as to control the
magnitude, duration, and quality of the immune response.
At this time, the basis for TLR/CD40 cross talk is not
782

known. Studies are underway to determine if signaling derived from TLR and CD40 agonists are directed at the same
or different cellular targets and whether signaling elements
common to both cascades may play a role in communications between these two receptor systems.
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